TY - JOUR AU - Cao, Han AU - Su, Shengmin AU - Yang, Qi AU - Le, Yunchen AU - Chen, Lihong AU - Hu, Mengyan AU - Guo, Xiaoyu AU - Zheng, Jie AU - Li, Xia AU - Yu, Yunqiu PY - 2021 DA - 2021/02/18 TI - Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients JO - Lipids in Health and Disease SP - 16 VL - 20 IS - 1 AB - Psoriasis is a common chronic inflammatory skin disease associated with overproduction of interleukin-17A (IL-17A). IL-17A monoclonal antibodies (mAbs) have shown clinical efficacy in psoriasis patients. Although a series of different overlapping mechanisms have been found to establish a link between psoriasis and cardiovascular diseases, the underlying mechanisms of the two types of diseases and the potential efficacy of IL-17A mAbs in amelioration of cardiovascular comorbidities remain unclear. SN - 1476-511X UR - https://doi.org/10.1186/s12944-021-01441-9 DO - 10.1186/s12944-021-01441-9 ID - Cao2021 ER -